PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00, A61K 48/00

A2

(11) International Publication Number: **WO 98/26061**

(43) International Publication Date: 18 June 1998 (18.06.98)

(21) International Application Number: PCT/US97/22740

(22) International Filing Date: 8 December 1997 (08.12.97)

(30) Priority Data:

60/032,145	9 December 1996 (09.12.96)	US
08/982,272	1 December 1997 (01.12.97)	US

(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, LU, MX, NO, NZ, PT, RU, SE, SG, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

Without international search report and to be republished upon receipt of that report.

(71) Applicant: UNIVERSITY OF CALIFORNIA [US/US]; Technology Transfer Office, Mail Code: 0093, 9500 Gilman Drive, La Jolla, CA 92093–0093 (US).

(72) Inventors: KIPPS, Thomas, J.; 661 South Nardo Road #10, Solana Beach, CA 92075 (US). SHARMA, Sanjai; 8520–K Via Mallorca, La Jolla, CA 92037 (US). CANTWELL, Mark; 3775–H Miramar Street, La Jolla, CA 92037 (US).


(74) Agents: GUISE, Jeffrey, W. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071–2066 (US).

Address changed
See PCT/IB/306

(54) Title: NOVEL EXPRESSION VECTORS CONTAINING ACCESSORY MOLECULE LIGAND GENES AND THEIR USE FOR IMMUNOMODULATION AND TREATMENT OF MALIGNANCIES AND AUTOIMMUNE DISEASE

(57) Abstract

This invention relates to genes which encode accessory molecule ligands and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the molecules of this invention are also discussed.



DOMAINS: I - Cytoplasmic Domain; II - Transmembrane Domain; III - Proximal Extracellular Domain; IV - Distal Extracellular Domain (putative soluble form)